[ad_1]
Kaptoge S, Pennells L, De Bacquer D, Cooney MT, Kavousi M, Stevens G, et al. World Well being Group heart problems danger charts: revised fashions to estimate danger in 21 international areas. Lancet Glob Well being. 2019;7:e1332–45.
Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. International Burden of Cardiovascular Illnesses and Danger Elements, 1990–2019. J Am Coll Cardiol. 2020;76:2982–3021.
Wang X, Peter Okay. Molecular imaging of atherothrombotic ailments: seeing is believing. Arterioscler Thromb Vasc Biol. 2017;37:1029–40.
Banerjee C, Chimowitz MI. Stroke attributable to atherosclerosis of the most important intracranial arteries. Circ Res. 2017;120:502–23.
Zhu Y, Xian X, Wang Z, Bi Y, Chen Q, Han X, et al. Analysis progress on the connection between atherosclerosis and irritation. Biomolecules. 2018;8:80.
Lechner Okay, von Schacky C, McKenzie AL, Worm N, Nixdorff U, Lechner B, et al. Life-style components and high-risk atherosclerosis: pathways and mechanisms past conventional danger components. Eur J Prev Cardiol. 2020;27:394–406.
Lu W, Yao J, Zhu X, Qi Y. Nanomedicines: redefining conventional medication. Biomed Pharmacother Biomedecine Pharmacother. 2021;134:111103.
McFadyen JD, Schaff M, Peter Okay. Present and future antiplatelet therapies: emphasis on preserving haemostasis. Nat Rev Cardiol. 2018;15:181–91.
Scott AM, Wolchok JD, Previous LJ. Antibody remedy of most cancers. Nat Rev Most cancers. 2012;12:278–87.
Zhang L, McCabe T, Condra JH, Ni YG, Peterson LB, Wang W, et al. An anti-PCSK9 antibody reduces LDL-cholesterol on high of a statin and suppresses hepatocyte SREBP-regulated genes. Int J Biol Sci. 2012;8:310–27.
Flores AM, Ye J, Jarr Okay-U, Hosseini-Nassab N, Smith BR, Leeper NJ. Nanoparticle remedy for vascular ailments. Arterioscler Thromb Vasc Biol. 2019;39:635–46.
Chenthamara D, Subramaniam S, Ramakrishnan SG, Krishnaswamy S, Essa MM, Lin F-H, et al. Therapeutic efficacy of nanoparticles and routes of administration. Biomater Res. 2019;23:20.
Hoshyar N, Grey S, Han H, Bao G. The impact of nanoparticle dimension on in vivo pharmacokinetics and mobile interplay. Nanomed. 2016;11:673–92.
Anselmo AC, Mitragotri S. Cell-mediated supply of nanoparticles: benefiting from circulatory cells to focus on nanoparticles. J Managed Launch. 2014;190:531–41.
Wang X, Ziegler M, McFadyen JD, Peter Okay. Molecular imaging of arterial and venous thrombosis. Br J Pharmacol. 2021;178:4246–69.
Badimon L, Padró T, Vilahur G. Atherosclerosis, platelets and thrombosis in acute ischaemic coronary heart illness. Eur Coronary heart J Acute Cardiovasc Care. 2012;1:60–74.
Bryan MT, Duckles H, Feng S, Hsiao ST, Kim HR, Serbanovic-Canic J, et al. Mechanoresponsive networks controlling vascular irritation. Arterioscler Thromb Vasc Biol. 2014;34:2199–205.
Cook dinner-Mills JM, Marchese ME, Abdala-Valencia H. Vascular cell adhesion molecule-1 expression and signaling throughout illness: regulation by reactive oxygen species and antioxidants. Antioxid Redox Sign. 2011;15:1607–38.
Liang S, Zhang J, Ning R, Du Z, Liu J, Batibawa JW, et al. The crucial position of endothelial operate in effective particulate matter-induced atherosclerosis. Half Fibre Toxicol. 2020;17:61.
Ramji DP, Davies TS. Cytokines in atherosclerosis: key gamers in all levels of illness and promising therapeutic targets. Cytokine Progress Issue Rev. 2015;26:673–85.
Bennett MR, Sinha S, Owens GK. Vascular clean muscle cells in atherosclerosis. Circ Res. 2016;118:692–702.
Moore KJ, Sheedy FJ, Fisher EA. Macrophages in atherosclerosis: a dynamic steadiness. Nat Rev Immunol. 2013;13:709–21.
Swirski FK, Pittet MJ, Kircher MF, Aikawa E, Jaffer FA, Libby P, et al. Monocyte accumulation in mouse atherogenesis is progressive and proportional to extent of illness. Proc Natl Acad Sci. 2006;103:10340–5.
Cohn J, Kamili A, Wat E, Chung RW, Tandy S. Dietary phospholipids and intestinal ldl cholesterol absorption. Vitamins. 2010;2:116–27.
Luo J, Yang H, Track B-L. Mechanisms and regulation of ldl cholesterol homeostasis. Nat Rev Mol Cell Biol. 2020;21:225–45.
Kiyosue A, Honarpour N, Kurtz C, Xue A, Wasserman SM, Hirayama A. A part 3 examine of evolocumab (AMG 145) in Statin-Handled Japanese sufferers at excessive cardiovascular danger. Am J Cardiol. 2016;117:40–7.
Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and scientific outcomes in sufferers with heart problems. N Engl J Med. 2017;376:1713–22.
Walpola PL, Gotlieb AI, Cybulsky MI, Langille BL. Expression of ICAM-1 and VCAM-1 and monocyte adherence in arteries uncovered to altered shear stress. Arterioscler Thromb Vasc Biol. 1995;15:2–10.
Barrett TJ. Macrophages in atherosclerosis regression. Arterioscler Thromb Vasc Biol. 2020;40:20–33.
Leitinger N, Schulman IG. Phenotypic polarization of macrophages in atherosclerosis. Arterioscler Thromb Vasc Biol. 2013;33:1120–6.
McLaren JE, Michael DR, Ashlin TG, Ramji DP. Cytokines, macrophage lipid metabolism and foam cells: Implications for heart problems remedy. Prog Lipid Res. 2011;50:331–47.
Flynn MC, Pernes G, Lee MKS, Nagareddy PR, Murphy AJ. Monocytes, macrophages, and metabolic illness in atherosclerosis. Entrance Pharmacol. 2019;10:666.
Moore KJ, Freeman MW. Scavenger receptors in atherosclerosis: past lipid uptake. Arterioscler Thromb Vasc Biol. 2006;26:1702–11.
Kunjathoor VV, Febbraio M, Podrez EA, Moore KJ, Andersson L, Koehn S, et al. Scavenger receptors class A-I/II and CD36 are the principal receptors answerable for the uptake of modified low density lipoprotein resulting in lipid loading in macrophages. J Biol Chem. 2002;277:49982–8.
Meyer JM, Ji A, Cai L, van der Westhuyzen DR. Excessive-capacity selective uptake of cholesteryl ester from native LDL throughout macrophage foam cell formation. J Lipid Res. 2012;53:2081–91.
Younis N, Sharma R, Soran H, Charlton-Menys V, Elseweidy M, Durrington PN. Glycation as an atherogenic modification of LDL. Curr Opin Lipidol. 2008;19:378–84.
Zhao D, Li J, Xue C, Feng Okay, Liu L, Zeng P, et al. TL1A inhibits atherosclerosis in apoE-deficient mice by regulating the phenotype of vascular clean muscle cells. J Biol Chem. 2020;295:16314–27.
Chaabane C, Coen M, Bochaton-Piallat M-L. Easy muscle cell phenotypic swap: implications for foam cell formation. Curr Opin Lipidol. 2014;25:374–9.
Pugliese G, Iacobini C, Fantauzzi CB, Menini S. The darkish and shiny facet of atherosclerotic calcification. Atherosclerosis. 2015;238:220–30.
Rohwedder I, Montanez E, Beckmann Okay, Bengtsson E, Dunér P, Nilsson J, et al. Plasma fibronectin deficiency impedes atherosclerosis development and fibrous cap formation. EMBO Mol Med. 2012;4:564–76.
Björnheden T, Levin M, Evaldsson M, Wiklund O. Proof of hypoxic areas inside the arterial wall in vivo. Arterioscler Thromb Vasc Biol. 1999;19:870–6.
Doyle B, Caplice N. Plaque neovascularization and antiangiogenic remedy for atherosclerosis. J Am Coll Cardiol. 2007;49:2073–80.
Shah PK. Mechanisms of plaque vulnerability and rupture. J Am Coll Cardiol. 2003;41:S15-22.
Partida RA, Libby P, Crea F, Jang I-Okay. Plaque erosion: a brand new in vivo analysis and a possible main shift within the administration of sufferers with acute coronary syndromes. Eur Coronary heart J. 2018;39:2070–6.
Torii S, Sato Y, Otsuka F, Kolodgie FD, Jinnouchi H, Sakamoto A, et al. Eruptive Calcified Nodules as a Potential Mechanism of Acute Coronary Thrombosis and Sudden Demise. J Am Coll Cardiol. 2021;77:1599–611.
Moons AHM, Levi M, Peters RJG. Tissue issue and coronary artery diseaseq. Cardiovasc Res. 2002;13:1.
Pala R, Anju V, Dyavaiah M, Busi S, Nauli SM. Nanoparticle-mediated drug supply for the remedy of cardiovascular ailments. Int J Nanomedicine. 2020;15:3741–69.
Anselmo AC, Mitragotri S. Nanoparticles within the clinic: An replace. Bioeng Transl Med. 2019;4:e10143.
Stylianopoulos T, Jain RK. Design issues for nanotherapeutics in oncology. Nanomed Nanotechnol Biol Med. 2015;11:1893–907.
Akinc A, Maier MA, Manoharan M, Fitzgerald Okay, Jayaraman M, Barros S, et al. The Onpattro story and the scientific translation of nanomedicines containing nucleic acid-based medicine. Nat Nanotechnol. 2019;14:1084–7.
Baden LR, El Sahly HM, Essink B, Kotloff Okay, Frey S, Novak R, et al. Efficacy and security of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403–16.
Corbett KS, Flynn B, Foulds KE, Francica JR, Boyoglu-Barnum S, Werner AP, et al. Analysis of the mRNA-1273 Vaccine towards SARS-CoV-2 in nonhuman primates. N Engl J Med. 2020;383:1544–55.
Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. An mRNA vaccine towards SARS-CoV-2 — preliminary report. N Engl J Med. 2020;383:1920–31.
Khurana A, Allawadhi P, Khurana I, Allwadhi S, Weiskirchen R, Banothu AK, et al. Position of nanotechnology behind the success of mRNA vaccines for COVID-19. Nano As we speak. 2021;38:101142.
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Security and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603–15.
Duan H, Zhang Q, Liu J, Li R, Wang D, Peng W, et al. Suppression of apoptosis in vascular endothelial cell, the promising means for pure medicines to deal with atherosclerosis. Pharmacol Res. 2021;168:105599.
Estrada R, Giridharan G, Prabhu SD, Sethu P. Endothelial cell tradition mannequin of carotid artery atherosclerosis. Annu Int Conf IEEE Eng Med Biol Soc. 2011;2011:186–9.
Watson MG, Byrne HM, Macaskill C, Myerscough MR. A two-phase mannequin of early fibrous cap formation in atherosclerosis. J Theor Biol. 2018;456:123–36.
Manthe RL, Muro S. ICAM-1-targeted nanocarriers attenuate endothelial launch of soluble ICAM-1, an inflammatory regulator. Bioeng Transl Med. 2017;2:109–19.
Onat D, Brillon D, Colombo PC, Schmidt AM. Human vascular endothelial cells: a mannequin system for finding out vascular irritation in diabetes and atherosclerosis. Curr Diab Rep. 2011;11:193–202.
Park J-G, Ryu SY, Jung I-H, Lee Y-H, Kang KJ, Lee M-R, et al. Analysis of VCAM-1 antibodies as therapeutic agent for atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis. 2013;226:356–63.
Kheirolomoom A, Kim CW, Search engine optimization JW, Kumar S, Son DJ, Gagnon MKJ, et al. Multifunctional nanoparticles facilitate molecular focusing on and miRNA supply to inhibit atherosclerosis in ApoE –/– Mice. ACS Nano. 2015;9:8885–97.
Wang X, Searle AK, Hohmann JD, Liu AL, Abraham M-Okay, Palasubramaniam J, et al. Twin-targeted theranostic supply of miRs arrests stomach aortic aneurysm improvement. Mol Ther. 2018;26:1056–65.
Kumar S, Kim CW, Simmons RD, Jo H. Position of Circulate-sensitive microRNAs in endothelial dysfunction and atherosclerosis: mechanosensitive athero-miRs. Arterioscler Thromb Vasc Biol. 2014;34:2206–16.
Son DJ, Kumar S, Takabe W, Woo Kim C, Ni C-W, Alberts-Grill N, et al. The atypical mechanosensitive microRNA-712 derived from pre-ribosomal RNA induces endothelial irritation and atherosclerosis. Nat Commun. 2013;4:3000.
Fan D, Kassiri Z. Biology of tissue inhibitor of metalloproteinase 3 (TIMP3), and its therapeutic implications in cardiovascular pathology. Entrance Physiol. 2020;11:661.
Johnson JL, George SJ, Newby AC, Jackson CL. Divergent results of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries. Proc Natl Acad Sci. 2005;102:15575–80.
Shimizu Okay, Mitchell RN, Libby P. Irritation and mobile immune responses in stomach aortic aneurysms. Arterioscler Thromb Vasc Biol. 2006;26:987–94.
Golledge J, Muller J, Daugherty A, Norman P. Stomach aortic aneurysm: pathogenesis and implications for administration. Arterioscler Thromb Vasc Biol. 2006;26:2605–13.
Schober A, Nazari-Jahantigh M, Wei Y, Bidzhekov Okay, Gremse F, Grommes J, et al. MicroRNA-126-5p promotes endothelial proliferation and limits atherosclerosis by suppressing Dlk1. Nat Med. 2014;20:368–76.
Golledge J, Norman P. Atherosclerosis and stomach aortic aneurysm: trigger, response or frequent danger components? Arterioscler Thromb Vasc Biol. 2010;30:1075–7.
Li X, Xiao H, Lin C, Solar W, Wu T, Wang J, et al. Synergistic results of liposomes encapsulating atorvastatin calcium and curcumin and focusing on dysfunctional endothelial cells in lowering atherosclerosis. Int J Nanomedicine. 2019;14:649–65.
Tsoref O, Tyomkin D, Amit U, Landa N, Cohen-Rosenboim O, Kain D, et al. E-selectin-targeted copolymer reduces atherosclerotic lesions, opposed cardiac reworking, and dysfunction. J Managed Launch. 2018;288:136–47.
Ma S, Tian XY, Zhang Y, Mu C, Shen H, Bismuth J, et al. E-selectin-targeting supply of microRNAs by microparticles ameliorates endothelial irritation and atherosclerosis. Sci Rep. 2016;6:22910.
Ye Z, Zhang S, Liu Y, Wang S, Zhang J, Huang R. A Peptide analogue of selectin ligands attenuated atherosclerosis by inhibiting monocyte activation. Mediators Inflamm. 2019;2019:1–15.
Ueyama T, Ikeda H, Haramaki N, Kuwano Okay, Imaizumi T. Results of monoclonal antibody to p-selectin and analogue of Sialyl lewis X on cyclic stream variations in stenosed and endothelium-injured canine coronary arteries. Circulation. 1997;95:1554–9.
Ikeda H, Ueyama T, Murohara T, Yasukawa H, Haramaki N, Eguchi H, et al. Adhesive interplay between P-selectin and sialyl Lewis(x) performs an necessary position in recurrent coronary arterial thrombosis in canine. Arterioscler Thromb Vasc Biol. 1999;19:1083–90.
Jin Okay, Luo Z, Zhang B, Pang Z. Biomimetic nanoparticles for irritation focusing on. Acta Pharm Sin B. 2018;8:23–33.
Simion V, Constantinescu CA, Stan D, Deleanu M, Tucureanu MM, Butoi E, et al. P-selectin focused dexamethasone-loaded lipid nanoemulsions: a novel remedy to scale back vascular irritation. Mediators Inflamm. 2016;2016:1–15.
Mocanu CA, Fuior EV, Voicu G, Rebleanu D, Safciuc F, Deleanu M, et al. P-selectin focused RAGE-shRNA lipoplexes alleviate atherosclerosis-associated irritation. J Managed Launch. 2021;338:754–72.
Kona S, Dong J-F, Liu Y, Tan J, Nguyen KT. Biodegradable nanoparticles mimicking platelet binding as a focused and managed drug supply system. Int J Pharm. 2012;423:516–24.
Wadhwa A, Aljabbari A, Lokras A, Foged C, Thakur A. Alternatives and challenges within the supply of mRNA-based vaccines. Pharmaceutics. 2020;12:102.
Michel T, Luft D, Abraham M-Okay, Reinhardt S, Salinas Medina ML, Kurz J, et al. Cationic nanoliposomes Meet mRNA: environment friendly supply of modified mRNA utilizing hemocompatible and steady vectors for therapeutic purposes. Mol Ther – Nucleic Acids. 2017;8:459–68.
Abraham M-Okay, Peter Okay, Michel T, Wendel HP, Krajewski S, Wang X. Nanoliposomes for secure and environment friendly therapeutic mRNA supply: a step towards nanotheranostics in inflammatory and cardiovascular ailments in addition to most cancers. Nanotheranostics. 2017;1:154–65.
Kanthi YM, Sutton NR, Pinsky DJ. CD39: interface between vascular thrombosis and irritation. Curr Atheroscler Rep. 2014;16:425.
Dwyer KM, Robson SC, Nandurkar HH, Campbell DJ, Gock H, Murray-Segal LJ, et al. Thromboregulatory manifestations in human CD39 transgenic mice and the implications for thrombotic illness and transplantation. J Clin Make investments. 2004;113:1440–6.
Dosta P, Demos C, Ramos V, Kang DW, Kumar S, Jo H, et al. Supply of siRNA to endothelial cells in vivo utilizing lysine/histidine oligopeptide-modified poly(β-amino ester) nanoparticles. Cardiovasc Eng Technol. 2021;12:114–25.
Perni S, Preedy EC, Prokopovich P. Amplify antimicrobial picture dynamic remedy efficacy with poly-beta-amino esters (PBAEs). Sci Rep. 2021;11:7275.
Mitroulis I, Alexaki VI, Kourtzelis I, Ziogas A, Hajishengallis G, Chavakis T. Leukocyte integrins: Position in leukocyte recruitment and as therapeutic targets in inflammatory illness. Pharmacol Ther. 2015;147:123–35.
Podolnikova NP, Kushchayeva YS, Wu Y, Faust J, Ugarova TP. The Position of Integrins αMβ2 (Mac-1, CD11b/CD18) and αDβ2 (CD11d/CD18) in Macrophage Fusion. Am J Pathol. 2016;186:2105–16.
Peter Okay, Schwarz M, Conradt C, Nordt T, Moser M, Kübler W, et al. Heparin inhibits ligand binding to the leukocyte integrin Mac-1 (CD11b/CD18). Circulation. 1999;100:1533–9.
Siegel PM, Bojti I, Bassler N, Holien J, Flierl U, Wang X, et al. A DARPin focusing on activated Mac-1 is a novel diagnostic software and potential anti-inflammatory agent in myocarditis, sepsis and myocardial infarction. Fundamental Res Cardiol. 2021;116:17.
Katsuki S, Matoba T, Nakashiro S, Sato Okay, Koga J, Nakano Okay, et al. Nanoparticle-mediated supply of pitavastatin inhibits atherosclerotic plaque destabilization/rupture in mice by regulating the recruitment of inflammatory monocytes. Circulation. 2014;129:896–906.
Wang Y, Li L, Zhao W, Dou Y, An H, Tao H, et al. Focused remedy of atherosclerosis by a broad-spectrum reactive oxygen species scavenging nanoparticle with intrinsic anti-inflammatory exercise. ACS Nano. 2018;12:8943–60.
Li L, Guo J, Wang Y, Xiong X, Tao H, Li J, et al. A Broad-Spectrum ROS-eliminating materials for prevention of irritation and drug-induced organ toxicity. Adv Sci Weinh Baden-Wurtt Ger. 2018;5:1800781.
Duivenvoorden R, Tang J, Cormode DP, Mieszawska AJ, Izquierdo-Garcia D, Ozcan C, et al. A statin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque irritation. Nat Commun. 2014;5:3065.
Choudhury RP, Rong JX, Trogan E, Elmalem VI, Dansky HM, Breslow JL, et al. Excessive-density lipoproteins retard the development of atherosclerosis and favorably transform lesions with out suppressing indices of irritation or oxidation. Arterioscler Thromb Vasc Biol. 2004;24:1904–9.
Pászty C, Maeda N, Verstuyft J, Rubin EM. Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J Clin Make investments. 1994;94:899–903.
Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Clift SM. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature. 1991;353:265–7.
Sanchez-Gaytan BL, Fay F, Lobatto ME, Tang J, Ouimet M, Kim Y, et al. HDL-Mimetic PLGA nanoparticle to focus on atherosclerosis plaque macrophages. Bioconjug Chem. 2015;26:443–51.
Groner J, Goepferich A, Breunig M. Atherosclerosis: Typical consumption of cardiovascular medicine versus supply utilizing nanotechnology – a brand new probability for causative remedy? J Managed Launch. 2021;333:536–59.
CSL Behring. A Section 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Research to Examine the Efficacy and Security of CSL112 in Topics With Acute Coronary Syndrome [Internet]. clinicaltrials.gov; 2021 Nov. Report No.: NCT03473223. https://clinicaltrials.gov/ct2/present/NCT03473223
Chmielowski RA, Abdelhamid DS, Faig JJ, Petersen LK, Gardner CR, Uhrich KE, et al. Athero-inflammatory nanotherapeutics: Ferulic acid-based poly(anhydride-ester) nanoparticles attenuate foam cell formation by regulating macrophage lipogenesis and reactive oxygen species technology. Acta Biomater. 2017;57:85–94.
Chnari E, Nikitczuk JS, Wang J, Uhrich KE, Moghe PV. Engineered polymeric nanoparticles for receptor-targeted blockage of oxidized low density lipoprotein uptake and atherogenesis in macrophages. Biomacromol. 2006;7:1796–805.
Iverson NM, Plourde NM, Sparks SM, Wang J, Patel EN, Shah PS, et al. Twin use of amphiphilic macromolecules as ldl cholesterol efflux triggers and inhibitors of macrophage athero-inflammation. Biomaterials. 2011;32:8319–27.
Lewis DR, Petersen LK, York AW, Zablocki KR, Joseph LB, Kholodovych V, et al. Sugar-based amphiphilic nanoparticles arrest atherosclerosis in vivo. Proc Natl Acad Sci. 2015;112:2693–8.
Moretti A, Li Q, Chmielowski R, Joseph L, Moghe P, Uhrich Okay. Nanotherapeutics containing lithocholic acid-based amphiphilic scorpion-like macromolecules cut back in vitro irritation in macrophages: implications for atherosclerosis. Nanomaterials. 2018;8:84.
Chan JW, Lewis DR, Petersen LK, Moghe PV, Uhrich KE. Amphiphilic macromolecule nanoassemblies suppress clean muscle cell proliferation and platelet adhesion. Biomaterials. 2016;84:219–29.
Wallert M, Bauer J, Kluge S, Schmölz L, Chen Y-C, Ziegler M, et al. The vitamin E spinoff garcinoic acid from Garcinia kola nut seeds attenuates the inflammatory response. Redox Biol. 2019;24:101166.
Hood E, Simone E, Wattamwar P, Dziubla T, Muzykantov V. Nanocarriers for vascular supply of antioxidants. Nanomed. 2011;6:1257–72.
Beldman TJ, Senders ML, Alaarg A, Pérez-Medina C, Tang J, Zhao Y, et al. Hyaluronan nanoparticles selectively goal plaque-associated macrophages and enhance plaque stability in atherosclerosis. ACS Nano. 2017;11:5785–99.
Beldman TJ, Malinova TS, Desclos E, Grootemaat AE, Misiak ALS, van der Velden S, et al. Nanoparticle-aided characterization of arterial endothelial structure throughout atherosclerosis development and metabolic remedy. ACS Nano. 2019;13:13759–74.
Zhao Y, He Z, Gao H, Tang H, He J, Guo Q, et al. High-quality tuning of core-shell construction of hyaluronic acid/cell-penetrating peptides/sirna nanoparticles for enhanced gene supply to macrophages in antiatherosclerotic remedy. Biomacromol. 2018;19:2944–56.
Mu D, Li J, Qi Y, Solar X, Liu Y, Shen S, et al. Hyaluronic acid-coated polymeric micelles with hydrogen peroxide scavenging to encapsulate statins for assuaging atherosclerosis. J Nanobiotechnology. 2020;18:179.
Pan H, Palekar R, Hou Okay, Bacon J, Yan H, Springer L, et al. Anti-JNK2 peptide–siRNA nanostructures enhance plaque endothelium and cut back thrombotic danger in atherosclerotic mice. Int J Nanomed. 2018;13:5187–205.
Wang X, Temme S, Grapentin C, Palasubramaniam J, Walsh A, Krämer W, et al. Fluorine-19 magnetic resonance imaging of activated platelets. J Am Coronary heart Assoc. 2020;9:e016971.
Flögel U, Temme S, Jacoby C, Oerther T, Keul P, Flocke V, et al. Multi-targeted 1H/19F MRI unmasks particular hazard patterns for rising cardiovascular issues. Nat Commun. 2021;12:5847.
Walsh APG, Gordon HN, Peter Okay, Wang X. Ultrasonic particles: An method for focused gene supply. Adv Drug Deliv Rev. 2021;179:113998.
Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK. Peroxisome proliferator–activated receptor γ ligands inhibit improvement of atherosclerosis in LDL receptor–poor mice. J Clin Make investments. 2000;106:523–31.
Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor gamma is a destructive regulator of macrophage activation. Nature. 1998;391:4.
Giacalone G, Tsapis N, Mousnier L, Chacun H, Fattal E. PLA-PEG nanoparticles enhance the anti-inflammatory impact of rosiglitazone on macrophages by enhancing drug uptake in comparison with free rosiglitazone. Supplies. 2018;11:1845.
Gonzalez L, Trigatti BL. Macrophage apoptosis and necrotic core improvement in atherosclerosis: a quickly advancing area with scientific relevance to imaging and remedy. Can J Cardiol. 2017;33:303–12.
Martinet W, Coornaert I, Puylaert P, De Meyer GRY. Macrophage demise as a pharmacological goal in atherosclerosis. Entrance Pharmacol. 2019;10:306.
Simion V, Zhou H, Haemmig S, Pierce JB, Mendes S, Tesmenitsky Y, et al. A macrophage-specific lncRNA regulates apoptosis and atherosclerosis by tethering HuR within the nucleus. Nat Commun. 2020;11:6135.
Kojima Y, Volkmer J-P, McKenna Okay, Civelek M, Lusis AJ, Miller CL, et al. CD47-blocking antibodies restore phagocytosis and forestall atherosclerosis. Nature. 2016;536:86–90.
Wang L, Li H, Tang Y, Yao P. Potential mechanisms and results of efferocytosis in atherosclerosis. Entrance Endocrinol. 2021;11:585285.
Tavori H, Rashid S, Fazio S. On the operate and homeostasis of PCSK9: reciprocal interplay with LDLR and extra lipid results. Atherosclerosis. 2015;238:264–70.
Rashid S, Curtis DE, Garuti R, Anderson NN, Bashmakov Y, Ho YK, et al. Decreased plasma ldl cholesterol and hypersensitivity to statins in mice missing Pcsk9. Proc Natl Acad Sci. 2005;102:5374–9.
Fitzgerald Okay, Frank-Kamenetsky M, Shulga-Morskaya S, Liebow A, Bettencourt BR, Sutherland JE, et al. Impact of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin sort 9 (PCSK9) and the focus of serum LDL ldl cholesterol in wholesome volunteers: a randomised, single-blind, placebo-controlled, part 1 trial. Lancet. 2014;383:60–8.
Shi B, Keough E, Matter A, Leander Okay, Younger S, Carlini E, et al. Biodistribution of Small Interfering RNA on the organ and mobile ranges after lipid nanoparticle-mediated supply. J Histochem Cytochem. 2011;59:727–40.
Jensen KK, Tadin-Strapps M, Wang S, Hubert J, Kan Y, Ma Y, et al. Dose-dependent results of siRNA-mediated inhibition of SCAP on PCSK9, LDLR, and plasma lipids in mouse and rhesus monkey. J Lipid Res. 2016;57:2150–62.
Murphy BA, Tadin-Strapps M, Jensen Okay, Mogg R, Liaw A, Herath Okay, et al. siRNA-mediated inhibition of SREBP cleavage-activating protein reduces dyslipidemia in spontaneously dysmetabolic rhesus monkeys. Metabolism. 2017;71:202–12.
Tadin-Strapps M, Peterson LB, Cumiskey A-M, Rosa RL, Mendoza VH, Castro-Perez J, et al. siRNA-induced liver ApoB knockdown lowers serum LDL-cholesterol in a mouse mannequin with human-like serum lipids. J Lipid Res. 2011;52:1084–97.
Rayman MP. Selenium and human well being. The Lancet. 2012;379:1256–68.
Xiao S, Mao L, Xiao J, Wu Y, Liu H. Selenium nanoparticles inhibit the formation of atherosclerosis in apolipoprotein E poor mice by assuaging hyperlipidemia and oxidative stress. Eur J Pharmacol. 2021;902:174120.
Wadhwani SA, Shedbalkar UU, Singh R, Chopade BA. Biogenic selenium nanoparticles: present standing and future prospects. Appl Microbiol Biotechnol. 2016;100:2555–66.
Guo L, Xiao J, Liu H, Liu H. Selenium nanoparticles alleviate hyperlipidemia and vascular harm in ApoE-deficient mice by regulating ldl cholesterol metabolism and lowering oxidative stress. Metallomics. 2020;12:204–17.
He H, Wang J, Yannieb PJ, Korzunc WJ, Yang H, Ghosh S. Nanoparticle-based “Two-pronged” method to regress atherosclerosis by simultaneous modulation of ldl cholesterol inflow and efflux. 2020;13: 1.
Meneghini BC, Tavares ER, Guido MC, Tavoni TM, Stefani HA, Kalil-Filho R, et al. Lipid core nanoparticles as automobile for docetaxel reduces atherosclerotic lesion, irritation, cell demise and proliferation in an atherosclerosis rabbit mannequin. Vascul Pharmacol. 2019;9:1.
Shakeel F, Alanazi FK, Raish M, Haq N, Radwan AA, Alsarra IA. Pharmacokinetic and in vitro cytotoxic analysis of cholesterol-rich nanoemulsion of cholesteryl-succinyl-5-fluorouracil. J Mol Liq. 2015;211:164–8.
Basatemur GL, Jørgensen HF, Clarke MCH, Bennett MR, Mallat Z. Vascular clean muscle cells in atherosclerosis. Nat Rev Cardiol. 2019;16:727–44.
Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J. Danger of thrombosis in human atherosclerotic plaques: position of extracellular lipid, macrophage, and clean muscle cell content material. Coronary heart. 1993;69:377–81.
Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory Remedy with Canakinumab for Atherosclerotic Illness. N Engl J Med. 2017;377:1119–31.
Palekar RU, Vemuri C, Marsh JN, Arif B, Wickline SA. Antithrombin nanoparticles inhibit stent thrombosis in ex vivo static and stream fashions. J Vasc Surg. 2016;64:1459–67.
Zhang L, Li Z, Ye X, Chen Z, Chen Z-S. Mechanisms of thrombosis and analysis progress on focused antithrombotic medicine. Drug Discov As we speak. 2021;S1359644621002105.
Liu S, Feng X, Jin R, Li G. Tissue plasminogen activator-based nanothrombolysis for ischemic stroke. Professional Opin Drug Deliv. 2018;15:173–84.
Juenet M, Support-Launais R, Li B, Berger A, Aerts J, Ollivier V, et al. Thrombolytic remedy primarily based on fucoidan-functionalized polymer nanoparticles focusing on P-selectin. Biomaterials. 2018;156:204–16.
Hu J, Huang W, Huang S, ZhuGe Q, Jin Okay, Zhao Y. Magnetically lively Fe3O4 nanorods loaded with tissue plasminogen activator for enhanced thrombolysis. Nano Res. 2016;9:2652–61.
Halvorsen S, Andreotti F, ten Berg JM, Cattaneo M, Coccheri S, Marchioli R, et al. Aspirin remedy in main heart problems prevention. J Am Coll Cardiol. 2014;64:319–27.
Schrör Okay. Aspirin and platelets: the antiplatelet motion of aspirin and its position in thrombosis remedy and prophylaxis. Semin Thromb Hemost. 1997;23:349–56.
Jin S, Wang Y, Zhu H, Wang Y, Zhao S, Zhao M, et al. Nanosized aspirin-Arg-Gly-Asp-Val: supply of aspirin to thrombus by the goal service Arg-Gly-Asp-Val tetrapeptide. ACS Nano. 2013;7:7664–73.
Liao J, Ren X, Yang B, Li H, Zhang Y, Yin Z. Focused thrombolysis through the use of c-RGD-modified N, N, N-Trimethyl Chitosan nanoparticles loaded with lumbrokinase. Drug Dev Ind Pharm. 2019;45:88–95.
Ji H, Wang L, Bi H, Solar L, Cai B, Wang Y, et al. Mechanisms of lumbrokinase in safety of cerebral ischemia. Eur J Pharmacol. 2008;590:281–9.
Hu C-MJ, Fang RH, Wang Okay-C, Luk BT, Thamphiwatana S, Dehaini D, et al. Nanoparticle biointerfacing by platelet membrane cloaking. Nature. 2015;526:118–21.
Wang S, Wang R, Meng N, Guo H, Wu S, Wang X, et al. Platelet membrane-functionalized nanoparticles with improved focusing on potential and decrease hemorrhagic danger for thrombolysis remedy. J Managed Launch. 2020;328:78–86.
Wu J, Zhu H, Yang G, He J, Wang Y, Zhao S, et al. Design and synthesis of nanoscaled IQCA-TAVV as a supply system able to antiplatelet activation, focusing on arterial thrombus and releasing IQCA. Int J Nanomed. 2018;13:1139–58.
Li Z, Huang H, Huang L, Du L, Solar Y, Duan Y. Prevention of oxidized low density lipoprotein-induced endothelial cell harm by DA-PLGA-PEG-cRGD nanoparticles mixed with ultrasound. Int J Mol Sci. 2017;18:815.
Schwarz M, Meade G, Stoll P, Ylanne J, Bassler N, Chen YC, et al. Conformation-specific blockade of the integrin GPIIb/IIIa: a novel antiplatelet technique that selectively targets activated platelets. Circ Res. 2006;99:25–33.
Weisser NE, Corridor JC. Purposes of single-chain variable fragment antibodies in therapeutics and diagnostics. Biotechnol Adv. 2009;27:502–20.
Wang X, Palasubramaniam J, Gkanatsas Y, Hohmann JD, Westein E, Kanojia R, et al. In the direction of efficient and secure thrombolysis and thromboprophylaxis: preclinical testing of a novel antibody-targeted recombinant plasminogen activator directed towards activated platelets. Circ Res. 2014;114:1083–93.
Bienvenu LA, Maluenda A, McFadyen JD, Searle AK, Yu E, Haller C, et al. Mixed antiplatelet/anticoagulant drug for cardiac ischemia/reperfusion harm. Circ Res. 2020;127:1211–3.
Wang X, Gkanatsas Y, Palasubramaniam J, Hohmann JD, Chen YC, Lim B, et al. Thrombus-targeted theranostic microbubbles: a brand new expertise in the direction of concurrent speedy ultrasound analysis and bleeding-free fibrinolytic remedy of thrombosis. Theranostics. 2016;6:726–38.
Granja T, Körner A, Glück C, Hohmann JD, Wang X, Köhler D, et al. Concentrating on CD39 towards activated platelets reduces systemic irritation and improves survival in sepsis: a preclinical pilot examine. Crit Care Med. 2019;47:e420–7.
Hohmann JD, Wang X, Krajewski S, Selan C, Haller CA, Straub A, et al. Delayed focusing on of CD39 to activated platelet GPIIb/IIIa through a single-chain antibody: breaking the hyperlink between antithrombotic efficiency and bleeding? Blood. 2013;121:3067–75.
Ziegler M, Hohmann JD, Searle AK, Abraham M-Okay, Nandurkar HH, Wang X, et al. A single-chain antibody-CD39 fusion protein focusing on activated platelets protects from cardiac ischaemia/reperfusion harm. Eur Coronary heart J. 2018;39:111–6.
Hanjaya-Putra D, Haller C, Wang X, Dai E, Lim B, Liu L, et al. Platelet-targeted twin pathway antithrombotic inhibits thrombosis with preserved hemostasis. JCI Perception. 2018;3:e99329.
Gunawan ST, Kempe Okay, Bonnard T, Cui J, Alt Okay, Legislation LS, et al. Multifunctional thrombin-activatable polymer capsules for particular focusing on to activated platelets. Adv Mater. 2015;27:5153–7.
Kim W, Haller C, Dai E, Wang X, Hagemeyer CE, Liu DR, et al. Focused antithrombotic protein micelles. Angew Chem Int Ed. 2015;54:1461–5.
Zaitsev S, Kowalska MA, Neyman M, Carnemolla R, Tliba S, Ding B-S, et al. Concentrating on recombinant thrombomodulin fusion protein to purple blood cells offers multifaceted thromboprophylaxis. Blood. 2012;119:4779–85.
Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua S. Advances and challenges of liposome assisted drug supply. Entrance Pharmacol. 2015;6:286.
Refaat A, del Rosal B, Palasubramaniam J, Pietersz G, Wang X, Moulton SE, et al. Close to-infrared light-responsive liposomes for protein supply: in the direction of bleeding-free photothermally-assisted thrombolysis. J Managed Launch. 2021;337:212–23.
Refaat A, del Rosal B, Palasubramaniam J, Pietersz G, Wang X, Peter Okay, et al. Sensible supply of plasminogen activators for environment friendly thrombolysis; latest tendencies and future views. Adv Ther. 2021;4:2100047.
Cicha I, Chauvierre C, Texier I, Cabella C, Metselaar JM, Szebeni J, et al. From design to the clinic: sensible pointers for translating cardiovascular nanomedicine. Cardiovasc Res. 2018;114:1714–27.
Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-based medicines: a evaluation of FDA-approved supplies and scientific trials thus far. Pharm Res. 2016;33:2373–87.
Iafisco M, Alogna A, Miragoli M, Catalucci D. Cardiovascular nanomedicine: the route forward. Nanomed. 2019;14:2391–4.
Searle AK, Chen YC, Wallert M, McFadyen J, Maluenda A, Noonan J, et al. Pharmacological inhibition of Issue XIIa attenuates stomach aortic aneurysm, reduces atherosclerosis, and stabilizes atherosclerotic plaques. Thromb Haemost. 2021 (in press).
[ad_2]
